List of Excipients in Branded Drug PHOTOFRIN

Photofrin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Photofrin, the branded formulation of porfimer sodium, is a complex intravenous photodynamic therapy drug with a deliberately minimal excipient profile. Its commercial opportunity is not primarily a conventional generic-excipient play. The strongest opportunities are compatible diluent systems, light-protective packaging, sterile reconstitution components, hospital workflow products, and potentially improved formulations that preserve porfimer’s oligomer distribution and photodynamic activity.

The product’s key formulation constraint is that porfimer sodium is a heterogeneous mixture of porphyrin oligomers. Changes to pH, ionic strength, concentration, container materials, light exposure, or reconstitution conditions can affect aggregation, adsorption, stability, tissue distribution, and clinical performance.

What is Photofrin and how is it formulated?

Photofrin is an intravenous formulation of porfimer sodium used with laser light for photodynamic treatment. In the United States, Photofrin is approved for certain patients with obstructing esophageal cancer and for ablation of high-grade dysplasia in Barrett’s esophagus under specified clinical conditions.[1]

Photofrin formulation profile

Attribute	Publicly described product characteristic
Active ingredient	Porfimer sodium
Dosage form	Sterile lyophilized powder for injection
Vial strength	75 mg per vial
Reconstitution vehicle	5% Dextrose Injection, USP
Reconstituted concentration	Approximately 2.5 mg/mL
Administration	Intravenous infusion
Preservatives	Not used in the labeled formulation
Light sensitivity	Requires protection from light
Core formulation issue	Control of aggregation, oligomer composition, adsorption, and photochemical stability
U.S. NDA	NDA 020451, based on FDA product information and historical regulatory records

The labeled product is reconstituted with approximately 31.8 mL of 5% dextrose to produce the administration solution.[1] The label directs preparation and handling under controlled conditions, including protection from light. The approved formulation does not rely on a broad excipient system such as surfactants, cosolvents, or lipid carriers.

What excipients are used in Photofrin?

The principal formulation excipient is the dextrose-based reconstitution vehicle. The commercial vial contains the lyophilized porfimer sodium drug product, while 5% Dextrose Injection, USP is used for reconstitution before infusion.[1]

Excipient strategy in the approved product

The formulation strategy has four defining elements:

1. A lyophilized drug substance or drug product to improve storage stability.
2. A carbohydrate-based aqueous reconstitution vehicle.
3. No preservative system for the single-use injectable product.
4. Light-protective handling and packaging.

The absence of a conventional stabilizer package creates both a limitation and an opportunity. A limited excipient system reduces the risk of excipient-mediated toxicity and simplifies the finished product. It also leaves little room for casual reformulation because porfimer sodium’s physicochemical behavior is sensitive to its aqueous environment.

Why 5% dextrose matters

Dextrose is not simply an interchangeable diluent. Replacing it with saline, buffered water, or another infusion vehicle could alter:

• Porfimer aggregation and particle-size distribution.
• Drug adsorption to tubing, syringes, or infusion bags.
• Osmolality and local tolerability.
• Solution stability during preparation and infusion.
• Photophysical behavior, including light absorption and excited-state activity.
• The administered dose and exposure profile.

A commercial alternative should therefore begin with compatibility studies rather than excipient substitution. The burden is particularly high because porfimer sodium is a complex mixture rather than a single, fully defined small molecule.

What formulation patents protect Photofrin?

The original Photofrin patent estate was built around porphyrin compositions, preparation methods, photodynamic treatment methods, and pharmaceutical use. The principal commercial and regulatory barriers are now more likely to arise from product characterization, manufacturing controls, clinical bridging, and know-how than from long-lived composition patents.

Patent and exclusivity position

Photofrin received U.S. approval in the 1990s, with the Barrett’s esophagus indication added later. The product’s original U.S. regulatory exclusivity periods have expired. Public FDA Orange Book materials should be used to confirm the current patent listing and any remaining listed claims for NDA 020451.[2]

The practical position is:

Protection category	Commercial relevance
Original composition patents	Generally historical and likely expired
Early photodynamic-treatment patents	Mostly expired or limited by claim scope and jurisdiction
Orange Book patents	Must be verified against the current NDA listing
Formulation patents	Potentially available for new products, but not automatically inherited from Photofrin
Method-of-use patents	May remain relevant in selected jurisdictions or new disease indications
Manufacturing know-how	Potentially significant because porfimer sodium is heterogeneous
Regulatory exclusivity	Original exclusivity has expired
Biosimilar exclusivity	Not applicable in the ordinary biologic sense

Are generic companies likely to challenge Photofrin?

A conventional ANDA route may be less straightforward than for a standard small-molecule injection. Porfimer sodium is a complex oligomeric mixture, and a proposed product would need to establish pharmaceutical equivalence and demonstrate adequate comparability in critical quality attributes.

A challenger could pursue:

• An ANDA, if FDA determines that the product can be adequately characterized and compared through the abbreviated pathway.
• A 505(b)(2) application for a modified formulation, delivery system, or presentation.
• A full or hybrid application if the proposed product departs materially from the reference formulation.
• A product based on a different photosensitizer rather than a Photofrin copy.

Publicly visible commercial activity does not establish a significant current Paragraph IV challenge to Photofrin. The main competitive threat is more likely to come from alternative photodynamic agents and improved treatment platforms than from a high-volume conventional generic.

What FDA regulatory pathway applies to a new Photofrin formulation?

A new Photofrin formulation would likely require a case-specific FDA pathway analysis. The pathway depends on whether the product preserves the reference formulation or changes the drug product, administration system, concentration, excipients, or clinical use.

Potential pathways

ANDA

An ANDA would be most plausible for a product that matches the reference product in active ingredient, strength, dosage form, route, and key performance characteristics. For porfimer sodium, the central issue would be whether the oligomeric mixture can be adequately defined and shown to be equivalent.

Critical evidence could include:

• Oligomer distribution.
• Molecular-weight profile.
• UV-visible absorption spectrum.
• Photodynamic activity.
• Aggregation and particle-size measurements.
• Impurity and degradation profiles.
• In vitro release or infusion performance.
• Stability under labeled storage and administration conditions.

505(b)(2)

A 505(b)(2) application could be more commercially realistic for:

• A ready-to-use formulation.
• A new reconstitution system.
• A different container closure.
• A premeasured diluent presentation.
• A changed concentration.
• A reduced-light-exposure infusion system.
• A new indication supported by additional clinical data.

A 505(b)(2) product would still need to address whether formulation changes affect porfimer exposure, distribution, photosensitivity duration, treatment effectiveness, or adverse events.

Full application

A full application could be necessary if the product has a materially different active moiety, a new photosensitizer, a different mechanism, or insufficient reliance on Photofrin’s safety and efficacy findings.

What commercial opportunities exist in Photofrin excipients?

The largest opportunities are ancillary products that reduce preparation risk without changing the active formulation.

1. Photofrin-compatible reconstitution kits

A kit could combine:

• A validated 5% dextrose diluent.
• A sterile transfer device.
• Light-protective labeling.
• A syringe or vial adapter.
• An infusion-bag connection system.
• Preparation instructions linked to the approved dose.

The value proposition is operational. Hospitals could reduce compounding steps, preparation errors, waste, and light exposure. The kit would require compatibility, sterility, extractables and leachables, particulate, and usability validation.

2. Light-protective container and infusion systems

Porfimer sodium is photoactive by design, but uncontrolled ambient light exposure can compromise handling and create occupational or product-protection concerns. Commercial products could include:

• Amber or opaque infusion bags.
• Light-protective overwraps.
• Tubing covers.
• Opaque syringe systems.
• Validated transport containers.
• Pharmacy preparation enclosures.

These products may be regulated as medical devices, drug-device combinations, or packaging components depending on their claims and integration with Photofrin administration.

3. Ready-to-use or dual-chamber presentations

A ready-to-use liquid could reduce reconstitution errors but would create substantial stability and packaging challenges. A dual-chamber vial or bag could separate lyophilized porfimer sodium from the dextrose vehicle until use.

Presentation	Commercial benefit	Main technical barrier
Current lyophilized vial	Long-established reference presentation	Manual reconstitution
Ready-to-use solution	Simplified administration	Aqueous stability, aggregation, shelf life
Dual-chamber vial	Reduced preparation steps	Device complexity and container compatibility
Dual-chamber infusion bag	Integrated preparation and delivery	Sterility, mixing, adsorption, packaging validation
Prefilled syringe	Precise handling for selected doses	Dose flexibility and photostability
Concentrated solution	Lower infusion volume	Higher aggregation and dosing sensitivity

A ready-to-use product would have the highest commercial differentiation but also the highest development risk.

4. Low-adsorption administration components

Porfimer sodium may interact with glass, plastics, filters, and infusion tubing. A specialized administration set could use materials selected for low binding and low extractables.

Relevant development work includes:

• Comparative recovery after passage through tubing.
• Drug concentration at the beginning, middle, and end of infusion.
• Filter compatibility.
• Container closure integrity.
• Photostability under clinical lighting.
• Particulate generation.
• Compatibility with common hospital infusion pumps.

A validated low-adsorption system could be sold as a hospital-use consumable, licensed to the drug sponsor, or incorporated into a reformulated drug product.

How strong is the Photofrin formulation patent estate?

The historic patent estate is more important as prior art and freedom-to-operate context than as a clear barrier to modern ancillary products. New claims could still be developed around a specific formulation, container, preparation system, or administration method if the product produces a defensible technical result.

Patentable areas for a new entrant

Potential claim categories include:

• A porfimer sodium formulation with defined oligomer or aggregation parameters.
• A stabilizer system that maintains photodynamic activity.
• A reconstituted solution with specified pH, osmolality, and particle-size limits.
• A dual-chamber container that limits light exposure and degradation.
• A low-binding infusion assembly.
• A method for reducing dose loss during preparation and infusion.
• A photoprotective packaging system with validated transmission limits.
• A formulation with improved refrigerated or room-temperature stability.
• A method that reduces preparation time or product waste.

The strongest patents would need measurable performance advantages, not merely the use of a known diluent or conventional amber packaging.

What manufacturing and IP barriers affect Photofrin competitors?

The largest barrier is control of the active drug substance. Porfimer sodium is not a simple crystalline API with one molecular structure and a routine impurity profile. A competitor would need to control:

• Porphyrin oligomer distribution.
• Molecular-weight distribution.
• Residual solvents and process impurities.
• Metal content and other elemental impurities.
• Aggregation state.
• Optical absorption profile.
• Photodynamic potency.
• Sterility and endotoxin.
• Stability during lyophilization and reconstitution.

Manufacturing know-how

Process variables can influence the final drug product, including:

• Reaction conditions used to generate oligomers.
• Purification and fractionation.
• pH adjustment.
• Freeze-drying cycle.
• Reconstitution conditions.
• Container surface interactions.
• Exposure to light during production and packaging.

This creates a practical barrier even where core patents have expired. A technically acceptable copy may require extensive analytical method development and bridging studies.

Excipient and packaging freedom to operate

An excipient supplier should screen claims relating to:

• Porphyrin stabilization.
• Photodynamic drug delivery.
• Opaque or light-filtering containers.
• Infusion systems.
• Pharmaceutical compositions containing porfimer or related porphyrins.
• Reconstitution and administration methods.

Traditional excipients such as dextrose, mannitol, buffers, and common surfactants are unlikely to provide meaningful exclusivity alone. The commercial moat would come from a validated combination of excipient, container, process, and performance specification.

How does Photofrin compare with alternative photodynamic drugs?

Photofrin competes with newer photosensitizers and disease-specific photodynamic products, not only with potential generic versions.

Product or platform	Active agent	Formulation profile	Competitive implication
Photofrin	Porfimer sodium	Lyophilized IV product reconstituted with dextrose	Established clinical and regulatory history, but complex handling
Talaporfin-based products	Talaporfin sodium	Photosensitizer formulations vary by market	Potentially shorter photosensitivity or different treatment profile
Verteporfin	Verteporfin	Lyophilized injectable product with specialized reconstitution	Strong ophthalmic use, different clinical market
Topical photosensitizers	Various	Cream, gel, or topical systems	Avoid systemic infusion but limited to accessible lesions
Light-activated investigational agents	Various	Nanoparticle, liposomal, or targeted systems	Potential formulation differentiation and new indications

Photofrin’s commercial advantage is historical clinical adoption and an established photodynamic treatment workflow. Its disadvantages include prolonged photosensitivity management, complex preparation, and a relatively narrow treatment setting.

What revenue exposure and market opportunities exist?

Photofrin revenue is exposed to procedure volume rather than broad chronic-prescription demand. Its use depends on:

• Availability of trained clinicians.
• Access to compatible laser equipment.
• Reimbursement for photodynamic therapy.
• Patient selection.
• Hospital pharmacy willingness to manage a light-sensitive injectable.
• Competition from surgery, stenting, endoscopic ablation, radiation, and newer systemic therapies.

This structure favors high-value workflow products over low-margin excipient substitution. A manufacturer selling a preparation kit or administration system can target the same procedural centers without competing directly on the active pharmaceutical ingredient.

Commercial models

Component supplier

Supply compatible diluent bags, opaque overwraps, tubing, filters, or transfer devices to the product sponsor or hospitals.

Co-packaged drug-device product

Partner with the Photofrin marketing authorization holder to integrate a preparation or administration component into a regulated product.

505(b)(2) reformulation

Develop a new presentation with improved preparation, stability, or administration characteristics.

Hospital pharmacy platform

Offer validated preparation protocols, consumables, and quality-control tools to photodynamic therapy centers.

Licensing

License a container, low-adsorption material, light-protection technology, or ready-to-use formulation to the drug owner.

What licensing and partnership opportunities are most credible?

The most credible licensing opportunities are those that solve a documented handling or manufacturing problem:

1. A ready-to-use or dual-chamber presentation.
2. A validated light-protective infusion system.
3. A low-binding container and tubing platform.
4. A longer-stability reconstituted product.
5. A waste-reduction system for weight-based dosing.
6. A formulation that enables a new treatment site or outpatient setting.

A conventional excipient package without a demonstrated improvement in stability, safety, or administration would have limited licensing value. The strongest transaction structure would combine patent protection with regulatory data and a validated manufacturing process.

What generic launch scenarios exist for Photofrin?

Three launch scenarios are commercially plausible.

Scenario 1: Conventional injectable competitor

A company develops a closely comparable lyophilized porfimer sodium product. The main barriers are analytical comparability, active-substance manufacturing, and regulatory pathway selection. Price competition could be meaningful only if the product achieves reliable hospital adoption.

Scenario 2: Improved formulation through 505(b)(2)

A company introduces a simplified, light-protected, or ready-to-use presentation. The product could command a premium by reducing pharmacy labor, preparation risk, and wastage.

Scenario 3: Alternative photosensitizer

A competitor develops a different photosensitizer with shorter photosensitivity, improved tissue selectivity, easier administration, or a broader indication. This is the highest strategic threat to Photofrin but requires new clinical development.

What is the FDA and Orange Book status of Photofrin?

Photofrin is an FDA-approved prescription product marketed as porfimer sodium injection. Its U.S. regulatory foundation is NDA 020451.[1] The original product is no longer protected by the regulatory exclusivity periods associated with its 1990s approvals.

The current Orange Book should be reviewed for:

• Active patent listings.
• Patent-use codes.
• Any listed formulation or method-of-use patents.
• Reference product designation.
• Approved strengths and dosage forms.
• Current marketing status.[2]

Because Photofrin is an older product with a complex active ingredient, regulatory exclusivity is less likely to be the primary barrier than product-specific CMC and clinical comparability.

Key Takeaways

• Photofrin uses a minimal formulation centered on lyophilized porfimer sodium and 5% dextrose for reconstitution.
• Excipient substitution is technically sensitive because porfimer sodium is a heterogeneous oligomeric mixture.
• The best commercial opportunities are compatible diluent kits, light-protective packaging, low-adsorption administration systems, and dual-chamber presentations.
• A ready-to-use formulation could offer the greatest differentiation but would face substantial stability, aggregation, and regulatory challenges.
• Original Photofrin regulatory exclusivity has expired, while historical patent protection is unlikely to block all new formulation or device claims.
• Generic competition is possible, but analytical comparability and manufacturing know-how create barriers beyond ordinary injectable generics.
• The strongest licensing assets will combine a measurable handling or stability benefit, patentable implementation, and regulatory data.
• Alternative photosensitizers pose a larger long-term competitive threat than simple excipient substitution.

FAQs

Can Photofrin be reconstituted with normal saline?

The approved labeling specifies 5% Dextrose Injection, USP for reconstitution. Substitution with saline should not be treated as equivalent without supporting compatibility and regulatory data.[1]

Is Photofrin a biologic requiring biosimilar approval?

Photofrin is not generally managed as a conventional therapeutic biologic for biosimilar purposes. Its regulatory challenge is more likely to involve complex drug-product characterization and an ANDA or 505(b)(2) assessment.

Could a ready-to-use Photofrin formulation receive patent protection?

Yes. Patent protection could focus on a defined stable composition, aggregation profile, container system, reconstitution technology, or validated light-protection method. A claim based only on using a conventional excipient would be weaker.

What is the highest-value excipient opportunity for Photofrin?

The highest-value opportunity is a formulation or kit that reduces preparation steps while preserving porfimer sodium stability and photodynamic activity. A validated dual-chamber or ready-to-use system would have greater commercial value than an unmodified alternative diluent.

Does Photofrin require special infusion equipment?

Photofrin requires controlled preparation and light-protective handling. Specialized infusion components are commercially attractive when they demonstrate low drug adsorption, reduced light exposure, reliable dose delivery, and compatibility with approved administration procedures.

References

1. U.S. Food and Drug Administration. (n.d.). Photofrin (porfimer sodium) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (1998). Photofrin approval and prescribing information materials. FDA.

4. National Cancer Institute. (n.d.). Photodynamic therapy to treat cancer. National Institutes of Health.

5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

6. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.